Project Grant R01CA315856
Award Date 6/4/26
Completion Date 5/31/31
Dollars Obligated $682K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a Project Grant totaling $659,201 under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 30, 2031. The research focuses on elucidating the Integrated Stress Response (ISR) pathway in glioblastoma (GBM) pathogenesis and therapeutic resistance. The project investigates how the interplay between phosphorylated eukaryotic translation initiation factor 2A...
- Federal Grant Award Summary Massachusetts General Hospital (The General Hospital Corporation) received a $707,798 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2031. The award supports fundamental research to identify mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically develops treatment-refractory forms following standard-of-care...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a Project Grant of $352,080 on July 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research and development activities addressing a critical barrier to effective cancer immunotherapy. The award funds a two-year project through June 30, 2027, focused on engineering novel chimeric antigen receptor T-cell (CAR-T) therapies designed to overcome the cancer cell glycocalyx—a...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts Eye and Ear Infirmary a $437,113 Project Grant on June 8, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate an innovative imaging technology for quantifying PD-L1 (Programmed Death Ligand 1) target engagement in head and neck squamous cell carcinoma patients. The project, which runs through May 31, 2028, focuses on creating a fluorescence lifetime imaging (FLI)...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a Project Grant of $817,829 on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention designed to improve quality of life in early post-treatment lymphoma survivors (0-2 years post-treatment). The study will enroll 254 participants across three...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a Project Grant of $542,644 under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. This research grant supports the development and evaluation of improved cancer treatment methods through laboratory and clinical research. The grant funds a transformative approach utilizing radiation-guided antibody-drug conjugates (ADCs) for targeted delivery of cytotoxic...